Sort by
Refine Your Search
-
Listed
-
Category
-
Employer
- Delft University of Technology (TU Delft)
- Delft University of Technology (TU Delft); Delft
- Delft University of Technology (TU Delft); yesterday published
- University of Groningen
- Utrecht University
- Leiden University
- Amsterdam UMC
- Leiden University; 's-Gravenhage
- Maastricht University (UM)
- University of Twente
- Wageningen University & Research
- Amsterdam UMC; 27 Sep ’25 published
- Delft University of Technology (TU Delft); 26 Sep ’25 published
- Delft University of Technology (TU Delft); today published
- Erasmus MC (University Medical Center Rotterdam)
- Erasmus MC (University Medical Center Rotterdam); today published
- KNAW
- Maastricht University (UM); Maastricht
- Maastricht University (UM); yesterday published
- Nature Careers
- Princess Máxima Center for Pediatric Oncology
- Princess Máxima Center for Pediatric Oncology; Utrecht
- Radboud University
- Royal Netherlands Academy of Arts and Sciences (KNAW)
- Royal Netherlands Academy of Arts and Sciences (KNAW); Utrecht
- The Netherlands Cancer Institute
- The Netherlands Cancer Institute; Amsterdam
- University of Amsterdam (UvA)
- University of Amsterdam (UvA); 26 Sep ’25 published
- University of Groningen; Groningen
- University of Twente (UT)
- University of Twente (UT); yesterday published
- Wageningen University & Research; today published
- Wageningen University and Research Center
- 24 more »
- « less
-
Field
-
goal-oriented mindset, and a passion for (scientific) challenges, you are the right person for us. Our lab develops technologies that integrate advanced imaging, computational analysis, and single-cell
-
-oriented mindset, and a passion for (scientific) challenges, you are the right person for us. Our lab develops technologies that integrate advanced imaging, computational analysis, and single-cell & spatial
-
druggable targets for molecular subtypes in PD(D) using a disease subtype classification based on pathology or dysregulated cell biology. WP1. To generate well-defined iPSC and differentiate into neural cells
-
based on pathology or dysregulated cell biology. WP1. To generate well-defined iPSC and differentiate into neural cells that can be used for FTD and PD(D)/DLB subtype-tailored compound testing. WP2
-
. The tasks including but not limited to: Battery cell and system level models for both mature off-the-shelf (NMC) and emerging new batteries (solid-state) via a physics-informed data-driven approach. Accurate
-
of RNA therapeutics for the brain. The successful candidate will work at the interface of molecular biology, cell models of the blood–brain barrier, and advanced human in vitro systems such as induced
-
-fidelity battery system model ready for future digital twin development. The tasks including but not limited to: Battery cell and system level models for both mature off-the-shelf (NMC) and emerging new
-
work at the interface of molecular biology, cell models of the blood–brain barrier, and advanced human in vitro systems such as induced pluripotent stem cell (iPSC)-derived cultures and organoids. A key
-
. Wageningen University & Research encourages internal advancement opportunities and mobility with an internal recruitment policy. There are plenty of options for personal initiative in a learning environment
-
aging-associated mechanisms and the development of RNA therapeutics for the brain. The successful candidate will work at the interface of molecular biology, cell models of the blood–brain barrier, and